Roche agrees to acquire PathAI for 750 million dollars
Roche agreed to acquire PathAI for 750 million dollars upfront to expand digital pathology. This deal is expected to close in the second half of 2026.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR will acquire PathAI for $750 million upfront and up to $300 million in milestone payments. The deal follows a five-year partnership between Roche and PathAI that expanded in 2024. This acquisition integrates AI-enabled companion diagnostics into Roche's core pathology division to improve cancer treatment precision.
